Description: uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Home Page: www.uniqure.com
Paasheuvelweg 25
Amsterdam,
1105 BP
Netherlands
Phone:
31 20 240 6000
Officers
| Name | Title |
|---|---|
| Mr. Matthew Craig Kapusta CPA | CEO & Executive Director |
| Mr. Christian Klemt | CFO, Principal Financial Officer & GM of Amsterdam Site |
| Mr. Richard Porter Ph.D. | Chief Business & Scientific Officer |
| Dr. Jeannette Potts J.D., Ph.D. | Chief Legal & Compliance Officer and Corporate Secretary |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany |
| Dr. Amin Abujoub Ph.D. | Chief Technical Operations |
| Dr. Tamara Tugal Ph.D., MBA | Business Development Director |
| Ms. Erin Boyer | Chief People & Culture Officer |
| Dr. Walid Abi-Saab M.D. | Chief Medical Officer |
| Eileen Sawyer | Vice President of Global Medical Affairs |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 29.8507 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.5792 |
| Price-to-Sales TTM: | 10.6891 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 480 |